Preliminary study of the fibrin structure in hypertensive, dyslipidemic and type 2 diabetic patients. Report as inadecuate




Preliminary study of the fibrin structure in hypertensive, dyslipidemic and type 2 diabetic patients. - Download this document for free, or read online. Document in PDF available to download.

Nuris Suárez-Nieto ;Investigación Clínica 2010, 51 3

Author: Rita Marchi-Cappelletti

Source: http://www.redalyc.org/articulo.oa?id=372937681003


Teaser



Investigación Clínica ISSN: 0535-5133 riclinicas@gmail.com Universidad del Zulia Venezuela Marchi-Cappelletti, Rita; Suárez-Nieto, Nuris Preliminary study of the fibrin structure in hypertensive, dyslipidemic and type 2 diabetic patients. Investigación Clínica, vol.
51, núm.
3, 2010, pp.
315-324 Universidad del Zulia Maracaibo, Venezuela Available in: http:--www.redalyc.org-articulo.oa?id=372937681003 How to cite Complete issue More information about this article Journals homepage in redalyc.org Scientific Information System Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Non-profit academic project, developed under the open access initiative Invest Clin 51(3): 315 - 324, 2010 Preliminary study of the fibrin structure in hypertensive, dyslipidemic and type 2 diabetic patients. Rita Marchi-Cappelletti y Nuris Suárez-Nieto. Instituto Venezolano de Investigaciones Científicas, Centro de Medicina Experimental, Laboratorio de Fisiopatología, Sección Biología del Desarrollo de la Hemostasia. Caracas, Venezuela. Key words: polymerization, permeation, compaction, fibrin structure, fibrin lysis, hypertension, dyslipidemia, type 2 diabetes. Abstract.
Individuals with hypertension, dyslipidemia or diabetes are at a higher risk to suffer cardiovascular disease than other people; while impaired fibrin structure-function may contribute to further raise the cardiovascular risk in the former.
The purpose of this work was to study the fibrin network and fibrin degradation properties in hypertensive (HT) patients, pharmacologically treated, 124 ± 11 mmHg, systolic blood pressure, and 70 ± 10 mmHg, diastolic blood pressure, n = 12; metabolic dyslipidemic patients (DL), cholesterol: 5.7 ± 1.5 mmol-L, n = 10; patients with type 2 diabetes mellitus (T2D), fasting plasma glucose: 8.8 ± 2.2 mmol-L, n = 10; and a control group of healthy individuals, n = 9.
The fibrinogen concentration was determined by the gravimetric method.
Fibr...





Related documents